As usage of the medications increases, Circana research indicates deli and produce could be bright spots for spending.

The evolution of AI, more limited-time product offerings and GLP-1 use for weight loss are among the issues expected to play a more prominent role this year.

The New Year is a time of reflection and change for many Americans, who start each January with a clean slate and goals for the next 12 months.Many resolutions ...

Holiday weight gain hits home for many come January. These days, folks making resolutions to slim down and get fit have an ...

Sharon Mann has lost nearly 30 pounds since starting on Mounjaro, a GLP-1 medication. Dr. Sanjay Gupta reports.

Roche's strategic acquisition of Poseida Pharmaceuticals positions them as a leader in the allogeneic cell therapy market.

Diet food brands have been hit in recent years, but now GLP-1 drugs like Ozempic are hitting the market, will this spell the ...

Guidepoint Qsight, a leader in leveraging proprietary data to provide unmatched analytics solutions, today revealed new ...

Maridebart cafraglutide, a novel injectable GIP receptor antagonist/GLP-1 receptor agonist, reduced body weight by ...

LifeVantage's new MindBody GLP-1 System is riding the coattails of GLP-1 weight loss drugs. See why I rate LFVN stock as a ...

According to BMO Capital Markets, Medicare coverage of Lilly’s Zepbound opens the door to using secondary indications to ...

GP leaders across the country are advising practices to push back on private providers requesting input for weight-loss jab ...